{
    "clinical_study": {
        "@rank": "146484", 
        "arm_group": [
            {
                "arm_group_label": "Cabaletta 15gr", 
                "arm_group_type": "Experimental", 
                "description": "Cabaletta 15gr"
            }, 
            {
                "arm_group_label": "Cabaletta 30gr", 
                "arm_group_type": "Experimental", 
                "description": "Cabaletta 30gr"
            }
        ], 
        "brief_summary": {
            "textblock": "-  This is an exploratory, randomized, parallel-group, dose escalation and dose-controlled\n           study without a placebo arm.\n\n        -  Eligible patients will be randomized in a 1:1 ratio (double-blind) to receive Cabaletta\n           in 2 doses, once weekly for 22 weeks (total of 24 weeks of treatment)."
        }, 
        "brief_title": "Study To Assess Safety, Tolerability and Efficacy of Intravenous Cabaletta in Patients With Machado-Joseph Disease", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Machado-Joseph Disease / Spinocerebellar Ataxia 3", 
        "condition_browse": {
            "mesh_term": [
                "Machado-Joseph Disease", 
                "Spinocerebellar Ataxias", 
                "Spinocerebellar Degenerations"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Men and women, 18 - 75 years\n\n          2. Clinically diagnosed as Machado-Joseph disease/Spinocerebellar ataxia 3 confirmed by\n             genetic testing\n\n          3. With disease stage 2 or less\n\n          4. Stable doses of all medications for 30 days prior to study entry and for the duration\n             of the study.\n\n          5. Body Mass Index (BMI) \u226432 kg/m2.\n\n          6. Ability to ambulate with or without assistance\n\n        Exclusion Criteria:\n\n          1. Diabetes mellitus type 1 or 2\n\n          2. Other major diseases\n\n          3. Uncontrolled heart disease, chronic heart failure (CHF).\n\n          4. Other neurological diseases.\n\n          5. Ataxia derived from any other cause than genetically-confirmed spinocerebellar ataxia\n\n          6. Presence of psychosis, bipolar disorder, untreated depression\n\n          7. History of malignancy (except non-invasive skin malignancy)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 21, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02147886", 
            "org_study_id": "BB-MJD-201"
        }, 
        "intervention": [
            {
                "arm_group_label": "Cabaletta 15gr", 
                "description": "Cabaletta for IV infusion once weekly", 
                "intervention_name": "Cabaletta for IV infusion once weekly during 24 weeks", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cabaletta 30gr", 
                "intervention_name": "Cabaletta for IV infusion once weekly during 24 weeks", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "Randomized, parallel-group, and dose-controlled", 
        "lastchanged_date": "May 23, 2014", 
        "location": {
            "contact": {
                "email": "Carlos.Gordon@clalit.org.il", 
                "last_name": "Carlos Gordon, Prof."
            }, 
            "facility": {
                "address": {
                    "city": "Kfar Saba", 
                    "country": "Israel"
                }, 
                "name": "Meir Medical Center"
            }, 
            "investigator": {
                "last_name": "Carlos Gordon, Prof.", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Single-Center, Randomized, Double-Blind, Parallel-Group, Dose-Controlled Study, to Assess Safety, Tolerability and Efficacy of Intravenous Cabaletta\u00ae in Patients With Machado-Joseph Disease", 
        "other_outcome": {
            "description": "Assessment of disease biochemical marker neuron specific enolase (NSE) and protein S 100 B (S100B)", 
            "measure": "Biochemical marker", 
            "safety_issue": "No", 
            "time_frame": "27 weeks"
        }, 
        "overall_contact": {
            "email": "Carlos.Gordon@clalit.org.il", 
            "last_name": "Carlos Gordon, Prof."
        }, 
        "overall_official": {
            "affiliation": "Meir Medical Center Kfar Saba Israel", 
            "last_name": "Carlos Gordon, Prof.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Israel: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Safety will be evaluated on the basis of the following assessments:\nAdverse events , physical examination, 12-lead ECG, vital signs, safety laboratory evaluations", 
                "measure": "Adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "28 weeks"
            }, 
            {
                "description": "Safety will be evaluated on the basis of the following assessments:\nAdverse events , physical examination, 12-lead ECG, vital signs, safety laboratory evaluations", 
                "measure": "Physical examination", 
                "safety_issue": "Yes", 
                "time_frame": "28 weeks"
            }, 
            {
                "description": "Safety will be evaluated on the basis of the following assessments:\nAdverse events , physical examination, 12-lead ECG, vital signs, safety laboratory evaluations", 
                "measure": "Vital signs", 
                "safety_issue": "Yes", 
                "time_frame": "28weeks"
            }, 
            {
                "description": "Safety will be evaluated on the basis of the following assessments:\nAdverse events , physical examination, 12-lead ECG, vital signs, safety laboratory evaluations", 
                "measure": "12-lead ECG", 
                "safety_issue": "Yes", 
                "time_frame": "28weeks"
            }, 
            {
                "description": "Safety will be evaluated on the basis of the following assessments:\nAdverse events , physical examination, 12-lead ECG, vital signs, safety laboratory evaluations", 
                "measure": "Safety laboratory tests", 
                "safety_issue": "Yes", 
                "time_frame": "28weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02147886"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Changes in disease markers will be assessed based on the following assessments:\nScale for the Assessment and Rating of Ataxia (SARA); Neurological Examination Score for Spinocerebellar Ataxia (NESSCA); Change in BMI - screening, spinocerebellar Ataxia Functional Tests; quality of life", 
            "measure": "Disease markers", 
            "safety_issue": "No", 
            "time_frame": "27 weeks"
        }, 
        "source": "Bioblast Pharma Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bioblast Pharma Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}